Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
Now available on-demand! Cracking the code: learnings from oligonucleotide method development WATCH NOW

Poster: Comparative metabolomics analysis of prostate cancer cells with different ethnic and tumorigenic phenotypes (Waters Corporation)

7 Oct 2014
General interest

A comprehensive high-throughput lipidomics and metabolomics analysis of prostate cancer cells with different tumorigenic phenotypes reveal potential markers for aggressive disease.

Click here to view poster

Related Links

  • Waters Corporation

Top content

  • Novel blood testing technology for Alzheimer’s Bio-Hermes-002 study
  • Deeper than the definition: ADCs, UHPLC and superficially porous particle technology
  • Tracking brain injury after stroke

Related tags

cancer high-throughput metabolomics
Previous article Next article

Related articles

24 OCT 2011 CHROMATOGRAPHY
Global metabolic profiling (metabonomics/metabolomics) using dried blood spots: advantages and pitfalls
28 APR 2015 NEWS
Novel acoustic separation method for cancer cells in blood samples
21 AUG 2014 CLINICAL
Scientists move one step closer towards the early diagnosis of ovarian cancer
9 MAY 2025 CONFERENCE REPORTS
1M PMI: The launch event of the most ambitious study of human health in history?
22 MAY 2014 CLINICAL
Using bioanalysis for cancer diagnosis and prognosis
15 JUL 2014 GENERAL INTEREST
Application note: Quantitation of polar analytes in high organic solvents and enabling large volume injections on ekspertTM MicroLC 200 using Online-Dilution-and-Refocusing (ODR) (AB SCIEX)
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone